JOHNSON & JOHNSON (1JNJ.MI) Stock Overview
Europe - BIT:1JNJ - US4781601046 - Common Stock
1JNJ.MI Key Statistics, Chart & Performance
The current stock price of 1JNJ.MI is 165.22 EUR. In the past month the price increased by 22.57%.
1JNJ.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 51.44 | 678.23B | ||
| 1LLY.MI | ELI LILLY & CO | 51.45 | 678.33B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.82 | 444.61B | ||
| JNJ.DE | JOHNSON & JOHNSON | 18.3 | 394.53B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.45 | 248.76B | ||
| 1ROG.MI | ROCHE HOLDING AG-GENUSSCHEIN | 13.92 | 239.54B | ||
| NOT.DE | NOVARTIS AG-REG | 14.94 | 218.05B | ||
| 1NOVN.MI | NOVARTIS AG-REG | 14.99 | 218.75B | ||
| SAN.PA | SANOFI | 11.76 | 216.39B | ||
| 1SAN.MI | SANOFI | 11.8 | 217.12B | ||
| SNW.DE | SANOFI | 11.77 | 216.58B | ||
| NOV.DE | NOVO NORDISK A/S-B | 13.75 | 204.09B |
Related stock screener links
About 1JNJ.MI
Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,100 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Company Info
JOHNSON & JOHNSON
One Johnson & Johnson Plaza
New Brunswick NEW JERSEY US
Employees: 138100
Phone: 17325242455
JOHNSON & JOHNSON / 1JNJ.MI FAQ
What does 1JNJ do?
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,100 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Can you provide the latest stock price for JOHNSON & JOHNSON?
The current stock price of 1JNJ.MI is 165.22 EUR. The price increased by 0.25% in the last trading session.
Does 1JNJ stock pay dividends?
JOHNSON & JOHNSON (1JNJ.MI) has a dividend yield of 2.71%. The yearly dividend amount is currently 4.21.
How is the ChartMill rating for JOHNSON & JOHNSON?
1JNJ.MI has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Where is JOHNSON & JOHNSON (1JNJ.MI) stock traded?
1JNJ.MI stock is listed on the Euronext Milan exchange.
What is the market capitalization of 1JNJ stock?
JOHNSON & JOHNSON (1JNJ.MI) has a market capitalization of 397.91B EUR. This makes 1JNJ.MI a Mega Cap stock.
Can you provide the upcoming earnings date for JOHNSON & JOHNSON?
JOHNSON & JOHNSON (1JNJ.MI) will report earnings on 2026-01-21, after the market close.
1JNJ.MI Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to 1JNJ.MI.
1JNJ.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1JNJ.MI. 1JNJ.MI has only an average score on both its financial health and profitability.
1JNJ.MI Financial Highlights
Over the last trailing twelve months 1JNJ.MI reported a non-GAAP Earnings per Share(EPS) of 8.95. The EPS increased by 1.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25% | ||
| ROA | 11.72% | ||
| ROE | 28.88% | ||
| Debt/Equity | 0.61 |
1JNJ.MI Forecast & Estimates
31 analysts have analysed 1JNJ.MI and the average price target is 156.97 EUR. This implies a price decrease of -5% is expected in the next year compared to the current price of 165.22.
For the next year, analysts expect an EPS growth of 9.8% and a revenue growth 5.23% for 1JNJ.MI